Immune monitoring in COVID-19 patients

Key facts

Disease
COVID-19
start year
2020
Funder
NWO Netherlands
Principal Investigator
Prof dr CHJ van Eijck
Research Location
Netherlands
Lead Research Institution
Erasmus MC
Research Priority Alignment
N/A

Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

Currently it is not clear which patients who are admitted to the hospital with a SARS-CoV-2 infection will benefit from treatment or die. Clearly, the balanced immune system is lost in some of the SARS-CoV-2 infected patients which contributes to the progression in disease. We believe that monitoring the immunological changes induced by the SARS-CoV-2 virus will lead to discovering prognostic or predictive markers that may assist in decision making and offers therapeutic options.

Publicationslinked via Europe PMC

Last Updated:9 hours ago

View all publications at Europe PMC

Developing injury and illness epidemiology and surveillance in cycling (PhD Academy Award).

Effects of Hand-Rearing and Group Size on Chimpanzee (Pan troglodytes) Social Competence in Captivity.

Revisiting Spirituality in Physical Therapy Practice: Perceptions of US Practitioners.

Aflibercept for Wet Age-Related Macular Degeneration: A Prospective, Randomized Trial Comparing Treat-And-Extend and Fixed Bimonthly Dosing.

The Concentration and Duration of Lipopolysaccharide Stimulation Produce Different Cytokine Responses in an Ex Vivo Whole Blood Model in Horses.

History of Shrimp Farming and the Main Viral and Bacterial Diseases in Mexico.

Identification of Risk Factors in Patients with Recurrent Cystitis May Improve Individualized Management.

ISApl4, a New IS1595 Family Insertion Sequence Forming a Novel Pseudo-Compound Transposon That Confers Antimicrobial Multidrug Resistance in Actinobacillus pleuropneumoniae.